BioLineRx

BioLineRx Ltd., also known as BioLine, is an Israeli publicly traded biopharmaceutical company headquartered in Modi'in-Maccabim-Re'ut. The company was established in 2003 as a joint venture involving Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors. Rather than operating primarily as a broad commercial pharmaceutical manufacturer, BioLineRx has historically functioned as a drug-development business: it identifies or obtains promising therapeutic candidates, advances them through preclinical and clinical development, and uses licensing, co-development, and commercialization agreements to bring selected programs closer to the market. The company became one of Israel's more visible biotechnology issuers when it completed an initial public offering on the Tel Aviv Stock Exchange in February 2007. The offering raised approximately NIS 211 million, reported at the time as about US$50 million, and was described as the largest biotechnology IPO on the TASE up to that point. BioLineRx subsequently expanded its access to international capital markets when American depositary receipts began trading on the NASDAQ Capital Market in July 2011. Its shares are also traded on the Tel Aviv Stock Exchange under the symbol BLRX. BioLineRx's development history has included programs in neurology, psychiatry, cardiovascular medicine, infectious disease, inflammation, ophthalmology, dermatology, oncology, and hematology. Earlier pipeline assets included BL-1010 and BL-1021 for neuropathic pain, BL-1020 for schizophrenia, BL-1040 for cardiac repair following acute myocardial infarction, BL-1230 for dry-eye disease, BL-5010 for seborrheic keratosis, BL-7040 for inflammatory disease, and the hepatitis C programs BL-8020 and BL-8030. Several of these programs were partnered, discontinued, or superseded as the company's strategic emphasis evolved. The company's best-known later development program has been motixafortide, formerly designated BL-8040. Motixafortide is a CXCR4 antagonist developed for stem-cell mobilization and for investigational use in oncology, including pancreatic cancer. The program illustrates BioLineRx's business model: a proprietary or partnered candidate is advanced through clinical development while the company seeks regulatory, commercial, and development relationships that can support broader use. The oncology and hematology focus has become central to the company's identity, although the historical pipeline demonstrates a wider therapeutic scope. BioLineRx has also used partnerships to share development and commercialization responsibilities. In 2009 it entered a commercialization agreement with Ikaria Holdings for BL-1040, and in 2010 it reached an agreement with Cypress Bioscience concerning BL-1020. The Cypress arrangement was cancelled in 2011 after Cypress was acquired by Ramius. In January 2012, BioLine announced a collaboration with French pharmaceutical company Genoscience to develop and market BL-8020 for hepatitis C. At the end of 2014, Novartis acquired a 12.8 percent stake in BioLineRx as a strategic investment intended to provide access to Israeli-originated drug candidates. Management has changed over time. Morris Laster served as chief executive officer until 2009, followed by Kinneret Savitsky, who became CEO in early 2010. BioLineRx's chief operating officer Philip Serlin succeeded Savitsky as chief executive officer on October 10, 2016. The company remains a development-stage biotechnology enterprise whose prospects depend substantially on clinical results, regulatory decisions, partnership activity, financing, and the ability to commercialize or out-license successful candidates.

BioLineRx was founded in Israel in 2003 as a joint venture involving Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and additional investors. The company was designed as a drug-development platform rather than as a conventional large-scale pharmaceutical manufacturer. Its role was to identify promising compounds, coordinate preclinical and clinical work, and seek external partners for development and commercialization. The company entered the public markets through an initial public offering on the Tel Aviv Stock Exchange in February 2007. The offering raised about NIS 211 million, reported at approximately US$50 million, and was characterized at the time as the largest biotechnology IPO on the TASE. BioLineRx later broadened its investor base when its American depositary receipts began trading on the NASDAQ Capital Market in July 2011. It continues to be associated with both the Israeli and U.S. public markets under the ticker BLRX. During its earlier years, BioLineRx maintained a broad development portfolio. BL-1010 and BL-1021 were associated with oral treatments for neuropathic pain, while BL-1020 was an orally available GABA-enhanced antipsychotic candidate for schizophrenia. BL-1040 was a liquid polymer intended for injection after acute myocardial infarction and was invented by Smadar Cohen of Ben-Gurion University. Other historical programs included BL-1230 for dry-eye disease, BL-5010 for seborrheic keratosis, and BL-7040, an oral anti-inflammatory candidate associated with research by Hermona Soreq of the Hebrew University of Jerusalem. The company also pursued BL-8020 and BL-8030 for hepatitis C. Partnerships were a recurring element of BioLineRx's operating strategy. In 2009 the company entered into a commercialization agreement with Ikaria Holdings for BL-1040. In 2010 it reached an agreement with Cypress Bioscience concerning BL-1020, but that arrangement was cancelled in 2011 after Cypress was taken over by Ramius. In January 2012 BioLineRx announced a collaboration with Genoscience, a French pharmaceutical company, for joint development and marketing of BL-8020. These arrangements reflected the company's effort to combine internal development capabilities with the resources and commercial reach of larger or specialized partners. At the end of 2014, Novartis acquired a 12.8 percent stake in BioLineRx. The investment was described as a strategic move to obtain access to drug candidates sourced from Israel. It was an important indication of the potential value of BioLineRx's pipeline and of the broader Israeli biotechnology ecosystem in which the company operated. BioLineRx's leadership also changed during this period. Morris Laster served as chief executive officer until 2009. Kinneret Savitsky became CEO in early 2010, and Philip Serlin, previously the company's chief operating officer, replaced her on October 10, 2016. Over time, the company's strategic center shifted toward oncology and hematology, particularly through motixafortide, formerly known as BL-8040. Motixafortide has been developed for stem-cell mobilization and investigated in oncology settings including pancreatic cancer. The program became the clearest expression of BioLineRx's later identity as a clinical-stage biotechnology company focused on advancing specialized therapies through clinical development and partnering.

1. 2016Philip Serlin becomes CEO

   Philip Serlin succeeds Kinneret Savitsky as chief executive officer on October 10.

   Source
2. 2014Novartis takes a strategic stake

   Novartis acquires a 12.8 percent interest in BioLineRx at the end of the year.

   Source
3. 2012Genoscience hepatitis C collaboration

   BioLineRx announces a deal with Genoscience to jointly develop and market BL-8020 for hepatitis C.

   Source
4. 2011NASDAQ Capital Market trading begins

   BioLineRx American depositary receipts begin trading on the NASDAQ Capital Market in July.

   Source
5. 2007Initial public offering on the TASE

   The company completes an initial public offering on the Tel Aviv Stock Exchange in February, raising approximately NIS 211 million.

   Source
6. 2003BioLineRx is established

   BioLineRx is formed in Israel as a joint venture involving Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors.

   Source

Clinical-stage biopharmaceutical developer focused on oncology, hematology, immunology, and specialty medicines, with a partnership-oriented model for advancing drug candidates.

• Motixafortide (BL-8040)Oncology and hematology drug candidate

  Motixafortide, previously designated BL-8040, is a CXCR4 antagonist and BioLineRx's principal later-stage development program. The company has developed it for stem-cell mobilization and investigated it in oncology, including pancreatic cancer. Its development has been central to BioLineRx's shift from a diversified early pipeline toward a more concentrated oncology and hematology strategy.

• BL-1020Psychiatric drug candidate

  BL-1020 was described as an orally available GABA-enhanced antipsychotic candidate for schizophrenia. BioLineRx entered into a development and commercialization arrangement with Cypress Bioscience in 2010, but the agreement was cancelled in 2011 after Cypress was acquired by Ramius.

• BL-1040Cardiovascular drug candidate

  BL-1040 was a liquid polymer designed for injection in patients after acute myocardial infarction. The candidate was invented by Smadar Cohen of Ben-Gurion University and became the subject of a 2009 commercialization agreement between BioLineRx and Ikaria Holdings.

• BL-8020Antiviral drug candidate

  BL-8020 was an orally administered hepatitis C treatment candidate developed in collaboration with Genoscience. The companies announced a joint development and marketing arrangement in January 2012.

• BL-8030Antiviral drug candidate

  BL-8030 was described as a second-generation NS3 protease inhibitor intended for oral treatment of hepatitis C. The program formed part of BioLineRx's earlier infectious-disease pipeline.

• BL-1010 and BL-1021Neuropathic-pain drug candidates

  BL-1010 and BL-1021 were early pipeline compounds associated with orally available treatments for neuropathic pain. They illustrate the breadth of BioLineRx's historical portfolio before the company concentrated more heavily on oncology and hematology.

• BL-1230Ophthalmic drug candidate

  BL-1230 was described as a selective cannabinoid receptor type 2 agonist for dry-eye syndrome. It was one of the company's earlier specialty-medicine research programs.

• BL-5010Dermatology drug candidate

  BL-5010 was a cream candidate intended to treat seborrheic keratosis skin lesions. It belonged to BioLineRx's earlier dermatology-oriented pipeline.

• BL-7040Anti-inflammatory drug candidate

  BL-7040 was described as an orally available anti-inflammatory candidate associated with research by Hermona Soreq of the Hebrew University of Jerusalem.

• 2016Chief executive successionOther

  BioLineRx changed leadership as its pipeline and corporate strategy continued to develop.

  What changed. Chief operating officer Philip Serlin replaced Kinneret Savitsky as chief executive officer on October 10.

  Aftermath. Serlin became the company's chief executive; the cited material does not provide additional details about the transition.

  Source
• 2014Novartis strategic equity investmentM&A

  Novartis sought strategic access to drug candidates sourced from Israel.

  What changed. Novartis acquired a 12.8 percent stake in BioLineRx.

  Aftermath. The investment gave Novartis a minority strategic position in the company, while BioLineRx gained the visibility associated with participation by a major pharmaceutical company.

  Source
• 2012Joint development of BL-8020 with GenoscienceStrategy

  BioLineRx was pursuing an oral hepatitis C candidate and sought a specialized pharmaceutical partner.

  What changed. The company announced a deal with Genoscience to jointly develop and market BL-8020.

  Aftermath. The agreement expanded BioLineRx's external collaboration model in infectious disease; later results are not detailed in the cited material.

  Source
• 2010Partner BL-1020 with Cypress BioscienceStrategy

  BioLineRx sought a partner for development of its schizophrenia candidate BL-1020.

  What changed. BioLineRx entered into a commercialization agreement with Cypress Bioscience.

  Aftermath. The agreement was cancelled in 2011 after Cypress Bioscience was acquired by Ramius.

  Source
• 2009Partner BL-1040 commercializationStrategy

  BioLineRx needed external development and commercialization capacity for its cardiac-repair candidate BL-1040.

  What changed. The company entered into a commercialization agreement with Ikaria Holdings.

  Aftermath. The agreement made BL-1040 the subject of a formal external commercialization relationship; later development status is not specified in the cited material.

  Source

• 2016Philip Serlin becomes BioLineRx chief executive

  BioLineRx's chief operating officer Philip Serlin replaced Kinneret Savitsky as chief executive officer on October 10, 2016.

  Leadership change
  Source
• 2014Novartis acquires strategic stake in BioLineRx

  At the end of 2014, Novartis acquired a 12.8 percent stake in BioLineRx as a strategic investment connected with access to Israeli-originated drug candidates.

  M&A
  Source
• 2012BioLineRx and Genoscience agree to develop BL-8020

  BioLineRx announced a collaboration with French pharmaceutical company Genoscience to jointly develop and market BL-8020 for hepatitis C.

  Other
  Source
• 2011BioLineRx begins NASDAQ Capital Market trading

  BioLineRx's American depositary receipts began trading on the NASDAQ Capital Market in July 2011, adding a U.S. market listing to its Tel Aviv quotation.

  Other
  Source
• 2011BioLineRx cancels Cypress Bioscience agreement

  The company's agreement with Cypress Bioscience concerning BL-1020 was cancelled after Cypress was acquired by Ramius.

  M&A
  Source
• 2010Kinneret Savitsky becomes chief executive officer

  Kinneret Savitsky succeeded Morris Laster as BioLineRx's chief executive during the company's early public-company development period.

  Leadership change
  Source
• 2009BioLineRx enters commercialization agreement with Ikaria

  BioLineRx partnered with Ikaria Holdings to develop and commercialize BL-1040, a cardiac-repair candidate intended for use following acute myocardial infarction.

  M&A
  Source
• 2007BioLineRx completes Tel Aviv Stock Exchange initial public offering

  The company listed on the Tel Aviv Stock Exchange in February 2007 in an offering reported as approximately NIS 211 million, at the time described as the largest biotechnology IPO on that exchange.

  Other
  Source

1. BioLineRx
2. BioLineRx corporate website